Conscious sedation | General anaesthesia | p-value | |
All procedures | 49 | 44 | |
Age years | 58.2±13.7 | 61.3±14.0 | 0.28 |
Female | 19 (38.8) | 12 (27.3) | 0.34 |
Charlson comorbidity index | 0.86 | ||
0–1 (low) | 23 (46.9) | 19 (43.2) | |
2–3 (moderate) | 11 (22.4) | 11 (25.0) | |
≥4 (high) | 12 (24.5) | 14 (31.8) | |
Emotional state score | |||
Pre-procedure | 4.6±3.4 | 4.7±3.9 | 0.91 |
Post-procedure | 2.4±1.5 | 2.5±1.6 | 0.79 |
Procedure | 0.23 | ||
Standard bronchoscopy (not for investigation of malignancy) | 6 | 2 | |
Standard bronchoscopy (for investigation of malignancy) | 8 | 4 | |
TBLB | 6 | 4 | |
Convex EBUS TBNA | 12 | 13 | |
Radial EBUS guide sheath biopsy | 13 | 15 | |
Combined: TBLB/EBUS TBNA | 1 | 1 | |
Combined: EBUS TBNA/EBUS guide sheath | 1 | ||
Therapeutic bronchoscopy | 2 | 5 | |
All diagnostic procedures | 47 | 39 | |
Final diagnosis: malignant | 13 (27.7) | 18 (46.2) | 0.11 |
Nonsmall cell lung cancer | 13 | 13 | |
Small cell lung cancer | 0 | 0 | |
Lymphoma | 0 | 2 | |
Metastatic malignancy | 0 | 3 | |
Final diagnosis: nonmalignant | 34 (72.3) | 21 (53.8) | |
Sarcoidosis | 1 | 2 | |
Infective/inflammatory | 19 | 14 | |
Benign/no abnormality detected | 10 | 4 | |
Other | 4 | 1 | |
EBUS TBNA | 14 | 14 | |
Final diagnosis: malignant | 6 (42.9) | 9 (64.3) | 0.45 |
Nonsmall cell lung cancer | 6 | 7 | |
Small cell lung cancer | 0 | 0 | |
Lymphoma | 0 | 0 | |
Metastatic malignancy | 0 | 2 | |
Final diagnosis: nonmalignant | 8 (57.1) | 5 (35.7) | |
Sarcoidosis | 1 | 2 | |
Reactive (adequate sample) | 7 | 3 |
Data are presented as n, mean±sd or n (%), unless otherwise stated. TBLB: transbronchial lung biopsy; EBUS: endobronchial ultrasound; TBNA: transbronchial needle aspiration.